drugset / Trial / NCT06761911
BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to explore the real-world Chinese relapsed/refractory patients to evaluate the efficacy and safety of BV monotherapy or combination therapy in CHL patients. The main questions it aims to answer are: To evaluate the efficacy and toxicity of BV-containing regimen in relapsed/refractory CHL patients in China, and to provide reference for the rational and safe use of BV in clinical practice.
Timeline
- Start
- 2024-12-31
- Primary completion
- 2025-12-17
- Completion
- 2026-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bendamustine | Small molecule | 90 mg/m2 | — |
| Comparator | Brentuximab Vedotin | Monoclonal antibody | 1.2 mg/kg | — |
| Comparator | Brentuximab Vedotin | Monoclonal antibody | 1.8 mg/kg | — |
| Comparator | Sintilimab | Monoclonal antibody | 200 mg | — |
| Comparator | Tislelizumab | Monoclonal antibody | 200 mg | — |